FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

2. Issuer Name and Ticker or Trading Symbol

BCRX ]

	OMB APPROVAL									
OMB Number: 3235-028										
Estimated average burden										
Ĺ	I.									

10% Owner

below)

Other (specify

5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

Director

below)

Officer (give title

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting  $\mathsf{Person}^\star$ 

Sheridan William P

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

**BIOCRYST PHARMACEUTICALS INC** 

(Last) (First) (Middle) 4505 EMPEROR BLVD. SUITE 200						3. Date of Earliest Transaction (Month/Day/Year) 05/27/2021								Chief Medical Officer					
(Street) DURHAM NC 27703					_   4.	f Ame	endme	nt, Date d	of Origina	al File	d (Month/Da	Line	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting						
(City)	(S	tate)	(Zip)											Persor	1				
		Tak	ole I - No	n-Deri	vativ	e Se	curit	ties Ac	quired	, Dis	sposed o	f, or Be	neficiall	y Owned					
1. Title of Security (Instr. 3)		2. Trans Date (Month/		ıy/Year) if		2A. Deemed Execution Date, if any (Month/Day/Year)		ction Instr.	4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4			Securition Benefici	i. Amount of Securities Beneficially Dwned Following Reported		Direct Indirect tr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)						
Common	Stock <sup>(1)</sup>			05/27	7/2021	2021		M		24,959	A	\$4.73	39	9,434		D			
Common	Stock <sup>(1)</sup>			05/27	7/2021				М		35,701	A	\$5.59	75,135		1	D		
Common	Stock <sup>(1)</sup>			05/27	7/2021	2021		М		11,099	A	\$5.45	86,234		D				
Common	Stock <sup>(1)</sup>			05/27	/27/2021				S		71,759	D	\$15 <sup>(2)</sup>	14,475		D			
Common	Stock <sup>(1)</sup>			05/28	3/2021				М		21,614	A	\$4.73	36,089		) D			
Common	Stock <sup>(1)</sup>			05/28	3/2021				М		64,299	A	\$5.59	100	0,388	88 D			
Common	Stock <sup>(1)</sup>			05/28	3/2021				М		5,901	A	\$5.45	106	5,289	]	D		
			05/28	3/2021				S		91,814	D	\$15.02	(3) 14,475		]	D			
			Table II -								osed of, convertil			Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	Date,	4. Transa Code ( 8)		5. N of Deri Sec Acq (A) Disp of (I 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amour of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e C S F Illy C	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amount or Number of Shares						
Emp. Stock Option (Right to Buy) <sup>(1)</sup>	\$4.73	05/27/2021			M			24,959	03/01/20	013	03/01/2022	Common Stock	24,959	\$0	21,614		D		
Emp. Stock Option (Right to Buy) <sup>(1)</sup>	\$5.59	05/27/2021			M			35,701	03/09/20	015	03/09/2022	Common Stock	35,701	\$0	64,299		D		
Emp. Stock Option (Right to Buy) <sup>(1)</sup>	\$5.45	05/27/2021			M			11,099	05/13/20	015	08/08/2023	Common Stock	11,099	\$0 5,90		1 D			
Emp. Stock Option (Right to Buy) <sup>(1)</sup>	\$4.73	05/28/2021			M			21,614	03/01/20	013	03/01/2022	Common Stock	21,614	\$0 0		D			
Emp. Stock Option (Right to Buy) <sup>(1)</sup>	\$5.59	05/28/2021			M			64,299	03/09/20	015	03/09/2022	Common Stock	64,299	\$0	0		D		
Emp. Stock Option (Right to Buy) <sup>(1)</sup>	\$5.45	05/28/2021			M			5,901	05/13/2015		08/08/2023	Common Stock	5,901	\$0	\$0 0		D		
	n of Respons	Sec.														-			

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2020.

- 2. The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from \$15.00 to \$15.01. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
- 3. The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from \$15.00 to \$15.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

<u>/s/ Alane P. Barnes, by power of attorney</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.